X

Cancer Therapy Advisor

Cancer Therapy Advisor
HER2-Targeted Therapies Demonstrate Activity in a Range of Solid Tumor Types

The HER2-targeted drugs pertuzumab and trastuzumab were active in a variety of solid tumors with HER2 amplification/overexpression, but outcomes differed by KRAS status, according to results...

Cancer Therapy Advisor
07/07/2021
Adjuvant Radiation May Provide a Survival Benefit Over Salvage Radiation in High-Risk Prostate Cancer

Adjuvant RT after radical prostatectomy may offer greater benefit than early salvage RT in men with high-risk prostate cancer, according to results of a study published in the Journal of Clinical..

Cancer Therapy Advisor
07/01/2021
Platinum Agents Not Recommended as Adjuvant Therapy for Basal Subtype Triple-Negative Breast Cancer

Adjuvant treatment with platinum agents fails to improve outcomes in patients with basal subtype TNBC who had residual invasive disease after neoadjuvant chemotherapy.

Cancer Therapy Advisor
06/23/2021
Bone-Protecting Agents Reduce Fractures Associated With Treatment in Metastatic Castration-Resistant Prostate Cancer

Bone-protecting agents reduce the risk of bone fractures in patients with mCRPC who receive enzalutamide, with or without radium-223, according to results from a phase 3 trial.

Cancer Therapy Advisor
06/14/2021
Pasireotide Plus Everolimus Improves PFS in Advanced Neuroendocrine Tumors of the Lung or Thymus

Phase 2 data show a progression-free survival benefit with the combination of pasireotide and everolimus in patients with advanced neuroendocrine tumors of the lung or thymus.

Cancer Therapy Advisor
06/14/2021
PD-L1 Expression in Macrophage-Like Cells Linked to PFS After Immunotherapy in Non-Small Cell Lung Cancer

New research suggests the size of cancer-associated macrophage-like cells and the level of PD-L1 expression in these cells may predict treatment outcomes in patients with non-small cell lung cancer

Cancer Therapy Advisor
06/11/2021
Rising Incidence of Endometrial Cancer Linked to Obesity in Younger Women

An increase in endometrial cancer incidence among young adult women in the United States coincides with an increase in the prevalence of obesity in this population, according to researchers.

Cancer Therapy Advisor
06/21/2021
Pasireotide Plus Everolimus Improves PFS in Advanced Neuroendocrine Tumors of the Lung or Thymus

Phase 2 data show a progression-free survival benefit with the combination of pasireotide and everolimus in patients with advanced neuroendocrine tumors of the lung or thymus.

Cancer Therapy Advisor
06/14/2021
Final Results Support Pembrolizumab as Standard of Care in MSI-H/dMMR Metastatic Colorectal Cancer

Pembrolizumab significantly improved PFS, but not OS, when compared with chemotherapy in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer...

Cancer Therapy Advisor
06/14/2021
Capecitabine Maintenance Improves Progression-Free Survival in Metastatic Colorectal Cancer

Capecitabine maintenance improved PFS, but not OS, when compared with active monitoring in patients with metastatic colorectal cancer, according to data from the FOCUS4-N trial.

Cancer Therapy Advisor
06/10/2021
Subscribe to Cancer Therapy Advisor

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#f5ce42
#575662
#a60538
#49cde9
#c20fce
#d95d39
#eb5834